235 related articles for article (PubMed ID: 31862313)
1. Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model.
Huang L; Liu Y; Jiao Z; Wang J; Fang L; Mao J
Eur J Pharm Sci; 2020 Feb; 143():105199. PubMed ID: 31862313
[TBL] [Abstract][Full Text] [Related]
2. Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome.
Li L; Zhu M; Li DY; Guo HL; Hu YH; Xu ZY; Jing X; Chen F; Zhao F; Li YM; Xu J; Jiao Z
Int Immunopharmacol; 2021 Sep; 98():107827. PubMed ID: 34284341
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients.
Jing Y; Kong Y; Hou X; Liu H; Fu Q; Jiao Z; Peng H; Wei X
J Clin Pharm Ther; 2021 Aug; 46(4):1117-1128. PubMed ID: 33768546
[TBL] [Abstract][Full Text] [Related]
4. Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms.
Wang J; Huang L; Gao P; Hu Y; Ni Y; Zhu Z; Zhang L; Yang J; Zhang H; Fang L
Eur J Clin Pharmacol; 2021 Jan; 77(1):71-77. PubMed ID: 32803289
[TBL] [Abstract][Full Text] [Related]
5. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients.
Chen B; Shi HQ; Liu XX; Zhang WX; Lu JQ; Xu BM; Chen H
J Clin Pharm Ther; 2017 Dec; 42(6):679-688. PubMed ID: 28833329
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of tacrolimus in children with nephrotic syndrome.
Hao GX; Huang X; Zhang DF; Zheng Y; Shi HY; Li Y; Jacqz-Aigrain E; Zhao W
Br J Clin Pharmacol; 2018 Aug; 84(8):1748-1756. PubMed ID: 29637588
[TBL] [Abstract][Full Text] [Related]
8. Impact of
Huang L; Wang J; Yang J; Zhang H; Ni Y; Zhu Z; Wang H; Gao P; Wu Y; Mao J; Fang L
Pharmacogenomics; 2019 Oct; 20(15):1071-1083. PubMed ID: 31588879
[No Abstract] [Full Text] [Related]
9. Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients.
Zhu L; Yang J; Zhang Y; Jing Y; Zhang Y; Li G
Xenobiotica; 2015; 45(9):840-6. PubMed ID: 25869250
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.
Prytuła AA; Cransberg K; Bouts AH; van Schaik RH; de Jong H; de Wildt SN; Mathôt RA
Clin Pharmacokinet; 2016 Sep; 55(9):1129-43. PubMed ID: 27138785
[TBL] [Abstract][Full Text] [Related]
11. Effect of CYP3 A4, CYP3 A5 and ABCB1 gene polymorphisms on the clinical efficacy of tacrolimus in the treatment of nephrotic syndrome.
Li M; Xu M; Liu W; Gao X
BMC Pharmacol Toxicol; 2018 Apr; 19(1):14. PubMed ID: 29615122
[TBL] [Abstract][Full Text] [Related]
12. Effects of CYP3A5, ABCB1 and POR*28 polymorphisms on pharmacokinetics of tacrolimus in the early period after renal transplantation.
Ling J; Dong LL; Yang XP; Qian Q; Jiang Y; Zou SL; Hu N
Xenobiotica; 2020 Dec; 50(12):1501-1509. PubMed ID: 32453653
[TBL] [Abstract][Full Text] [Related]
13. Prospective population pharmacokinetic study of tacrolimus in adult recipients early after liver transplantation: A comparison of Michaelis-Menten and theory-based pharmacokinetic models.
Cai XJ; Li RD; Li JH; Tao YF; Zhang QB; Shen CH; Zhang XF; Wang ZX; Jiao Z
Front Pharmacol; 2022; 13():1031969. PubMed ID: 36438793
[No Abstract] [Full Text] [Related]
14. Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients.
Jalil MH; Hawwa AF; McKiernan PJ; Shields MD; McElnay JC
Br J Clin Pharmacol; 2014 Jan; 77(1):130-40. PubMed ID: 23738951
[TBL] [Abstract][Full Text] [Related]
15. Dosage optimization of tacrolimus based on the glucocorticoid dose and pharmacogenetics in adult patients with systemic lupus erythematosus.
Wang CB; Zhang YJ; Zhao MM; Zhao L
Int Immunopharmacol; 2023 Nov; 124(Pt A):110866. PubMed ID: 37678026
[TBL] [Abstract][Full Text] [Related]
16. Dosage Optimization Based on Population Pharmacokinetic Analysis of Tacrolimus in Chinese Patients with Nephrotic Syndrome.
Lu T; Zhu X; Xu S; Zhao M; Huang X; Wang Z; Zhao L
Pharm Res; 2019 Feb; 36(3):45. PubMed ID: 30719576
[TBL] [Abstract][Full Text] [Related]
17. Impact of Donor and Recipient
Shao J; Wang C; Fu P; Chen F; Zhang Y; Wei J
Ann Pharmacother; 2020 Jul; 54(7):652-661. PubMed ID: 31888346
[No Abstract] [Full Text] [Related]
18. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
[TBL] [Abstract][Full Text] [Related]
19. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients.
Han N; Yun HY; Hong JY; Kim IW; Ji E; Hong SH; Kim YS; Ha J; Shin WG; Oh JM
Eur J Clin Pharmacol; 2013 Jan; 69(1):53-63. PubMed ID: 22660440
[TBL] [Abstract][Full Text] [Related]
20. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
Yildirim E; Şahin G; Kaltuş Z; Çolak E
Clin Lab; 2019 Nov; 65(11):. PubMed ID: 31710427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
